Patents by Inventor Andrew R. Harrison

Andrew R. Harrison has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulating neuromuscular junction density changes in botulinum-toxin treated tissue
    Patent number: 8791072
    Abstract: A method may include administering botulinum toxin to a tissue of a patient and administering a neuropeptide of the CRF family to the tissue of the patient. In some examples, the botulinum toxin is periodically administered to the tissue of the patient and/or the neuropeptide of the CRF family is periodically administered to the tissue of the patient. The periods with which the botulinum toxin and the neuropeptide of the CRF family are administered may be the same or may be different. In some examples, the botulinum toxin and the neuropeptide of the CRF family are administered to the tissue at substantially the same time, while in other embodiments, the botulinum toxin and the neuropeptide of the CRF family are administered to the tissue at different times.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: July 29, 2014
    Inventors: Michael Shi-young Lee, Andrew R. Harrison, Linda K. McLoon
  • MODULATING NEUROMUSCULAR JUNCTION DENSITY CHANGES IN BOTULINUM-TOXIN TREATED TISSUE
    Publication number: 20120220533
    Abstract: A method may include administering botulinum toxin to a tissue of a patient and administering a neuropeptide of the CRF family to the tissue of the patient. In some examples, the botulinum toxin is periodically administered to the tissue of the patient and/or the neuropeptide of the CRF family is periodically administered to the tissue of the patient. The periods with which the botulinum toxin and the neuropeptide of the CRF family are administered may be the same or may be different. In some examples, the botulinum toxin and the neuropeptide of the CRF family are administered to the tissue at substantially the same time, while in other embodiments, the botulinum toxin and the neuropeptide of the CRF family are administered to the tissue at different times.
    Type: Application
    Filed: February 27, 2012
    Publication date: August 30, 2012
    Inventors: Michael Shi-young Lee, Andrew R. Harrison, Linda K. McLoon